Document:

Document

Exhibit 4.7

DESCRIPTION OF REGISTRANT’S SECURITIES
REGISTERED PURSUANT TO SECTION 12 OF THE
SECURITIES EXCHANGE ACT OF 1934

    Angion Biomedica Corp. has common stock, $0.01 par value per share, registered under Section 12 of the Securities Exchange Act of 1934, as amended (the Exchange Act), and listed on The Nasdaq Global Select Market under the trading symbol “ANGN.”  
DESCRIPTION OF CAPITAL STOCK
    The following summary describes our capital stock and the material provisions of our amended and restated certificate of incorporation, our amended and restated bylaws, the amended and restated investors’ rights agreement to which we and certain of our stockholders are parties and of the Delaware General Corporation Law. Because the following is only a summary, it does not contain all of the information that may be important to you. For a complete description, you should refer to our amended and restated certificate of incorporation, amended and restated bylaws and amended and restated investor rights agreement, copies of which are incorporated by reference as Exhibits 3.1, 3.2 and [4.3], respectively, to our Annual Report on Form 10-K.
General
        Our authorized capital stock consists of 300,000,000 shares of common stock, $0.01 par value per share, and 10,000,000 shares of preferred stock, $0.01 par value per share. 
Common Stock
Voting Rights
        Each holder of our common stock is entitled to one vote for each share on all matters submitted to a vote of the stockholders, including the election of directors. Our stockholders do not have cumulative voting rights in the election of directors. Accordingly, holders of a majority of the voting shares are able to elect all of the directors. In addition, the affirmative vote of holders of 662/3% of the voting power of all of the then outstanding voting stock is required to take certain actions, including amending certain provisions of our amended and restated certificate of incorporation, such as the provisions relating to amending our amended and restated bylaws, the classified board and director liability.
Dividends
        Subject to preferences that may be applicable to any then outstanding preferred stock, holders of our common stock are entitled to receive dividends, if any, as may be declared from time to time by our board of directors out of legally available funds.
Liquidation
        In the event of our liquidation, dissolution or winding up, holders of our common stock will be entitled to share ratably in the net assets legally available for distribution to stockholders after the payment of all of our debts and other liabilities and the satisfaction of any liquidation preference granted to the holders of any then outstanding shares of preferred stock.
Rights and Preferences
        Holders of our common stock have no preemptive, conversion, subscription or other rights, and there are no redemption or sinking fund provisions applicable to our common stock. The rights, preferences and privileges of the holders of our common stock are subject to and may be adversely affected by the rights of the holders of shares of any series of our preferred stock that we may designate in the future.
Fully Paid and Nonassessable
        All of our outstanding shares of common stock are fully paid and nonassessable.
Convertible Preferred Stock

        Our board of directors has the authority, without further action by our stockholders, to issue up to 10,000,000 shares of preferred stock in one or more series and to fix the rights, preferences, privileges and restrictions thereof. These rights, preferences and privileges could include dividend rights, conversion rights, voting rights, terms of redemption, liquidation preferences, sinking fund terms and the number of shares constituting, or the designation of, such series, any or all of which may be greater than the rights of our common stock. The issuance of our preferred stock could adversely affect the voting power of holders of common stock and the likelihood that such holders will receive dividend payments and payments upon our liquidation. In addition, the issuance of preferred stock could have the effect of delaying, deferring or preventing a change in control of our company or other corporate action. As of [February 9, 2021] no shares of preferred stock were outstanding. 
Registration Rights
        Under our registration rights agreement dated March 31, 2020, the holders of approximately [20.7] million shares of our common stock, or their transferees, have the right to require us to register their shares under the Securities Act so that those shares may be publicly resold, and the holders of approximately [20.7] million shares of our common stock, or their transferees, have the right to include their shares in any registration statement we file, in each case as described below.
Form S-3 Registration Rights
        Based on the number of shares outstanding as of [December 31, 2020], the holders of approximately [20.7] million shares of our common stock, or their transferees, are entitled to certain Form S-3 registration rights. The holders of at least 15% of these shares can make a written request that we register their shares on Form S-3 if we are eligible to file a registration statement on Form S-3 and if the aggregate price to the public of the shares offered is at least $1.0 million (before deductions of underwriters' commissions and expenses). These stockholders may make an unlimited number of requests for registration on Form S-3, but in no event shall we be required to file more than two registrations on Form S-3 in any given twelve-month period.
Expenses of Registration
        We will pay the registration expenses of the holders of the shares registered pursuant to the demand and Form S-3 registration rights described above.
Expiration of Registration Rights
        The demand and Form S-3 registration rights described above will expire, with respect to any particular stockholder, upon the earlier of five years after the consummation of our initial public offering in February 2021 or when that stockholder can sell all of its shares under Rule 144 of the Securities Act during any 90-day period (and without the requirement for the Company to be in compliance with the current public information required under Section c(1) of Rule 144 of the Securities Act).
Anti-Takeover Effects of Provisions of our Amended and Restated Certificate of Incorporation, our Amended and Restated Bylaws and Delaware Law
        Certain provisions of Delaware law and our amended and restated certificate of incorporation and our amended and restated bylaws contain provisions that could make the following transactions more difficult: acquisition of us by means of a tender offer; acquisition of us by means of a proxy contest or otherwise; or removal of our incumbent officers and directors. It is possible that these provisions could make it more difficult to accomplish or could deter transactions that stockholders may otherwise consider to be in their best interest or in our best interests, including transactions that might result in a premium over the market price for our shares.
        These provisions, summarized below, are expected to discourage coercive takeover practices and inadequate takeover bids. These provisions are also designed to encourage persons seeking to acquire control of us to first negotiate with our board of directors. We believe that the benefits of increased protection of our potential ability to negotiate with the proponent of an unfriendly or unsolicited proposal to acquire or restructure us outweigh the disadvantages of discouraging these proposals because negotiation of these proposals could result in an improvement of their terms.

Delaware Anti-Takeover Statute
        We are subject to Section 203 of the Delaware General Corporation Law, which prohibits persons deemed "interested stockholders" from engaging in a "business combination" with a publicly-held Delaware corporation for three years following the date these persons become interested stockholders unless the business combination is, or the transaction in which the person became an interested stockholder was, approved in a prescribed manner or another prescribed exception applies. Generally, an "interested stockholder" is a person who, together with affiliates and associates, owns or within three years prior to the determination of interested stockholder status did own, 15% or more of a corporation's voting stock. Generally, a "business combination" includes a merger, asset or stock sale or other transaction resulting in a financial benefit to the interested stockholder. The existence of this provision may have an anti-takeover effect with respect to transactions not approved in advance by the board of directors, such as discouraging takeover attempts that might result in a premium over the market price of our common stock.
Undesignated Preferred Stock
        The ability to authorize undesignated preferred stock makes it possible for our board of directors to issue preferred stock with voting or other rights or preferences that could impede the success of any attempt to change control of us. These and other provisions may have the effect of deterring hostile takeovers or delaying changes in control or management of our company.
Special Stockholder Meetings
        Our amended and restated bylaws provide that a special meeting of stockholders may be called at any time by our board of directors or the chairperson of the Board of Directors or our President or Chief Executive Officer, but such special meetings may not be called by the stockholders or any other person or persons.
Requirements for Advance Notification of Stockholder Nominations and Proposals
        Our amended and restated bylaws establish advance notice procedures with respect to stockholder proposals and the nomination of candidates for election as directors, other than nominations made by or at the direction of the board of directors or a committee of the board of directors.
Elimination of Stockholder Action by Written Consent
        Our amended and restated certificate of incorporation and our amended and restated bylaws eliminated the right of stockholders to act by written consent without a meeting.
Classified Board; Election and Removal of Directors; Filling Vacancies
    Our board of directors is divided into three classes. The directors in each class will serve for a three-year term, one class being elected each year by our stockholders, with staggered three-year terms. Only one class of directors will be elected at each annual meeting of our stockholders, with the other classes continuing for the remainder of their respective three-year terms. Because our stockholders do not have cumulative voting rights, our stockholders holding a majority of the shares of our common stock outstanding will be able to elect all of our directors. Our amended and restated certificate of incorporation provides for the removal of any of our directors only for cause and requires a stockholder vote by the holders of at least a 662/3% of the voting power of the then outstanding voting stock. Furthermore, any vacancy on our board of directors, however occurring, including a vacancy resulting from an increase in the size of the board, may only be filled by a resolution of the board of directors unless the board of directors determines that such vacancies shall be filled by the stockholders. This system of electing and removing directors and filling vacancies may tend to discourage a third party from making a tender offer or otherwise attempting to obtain control of us, because it generally makes it more difficult for stockholders to replace a majority of the directors.
Choice of Forum
        Our amended and restated certificate of incorporation and amended and restated bylaws provide that, unless we consent in writing to the selection of an alternative forum, the Court of Chancery of the 

State of Delaware will be the exclusive forum for the following types of actions or proceedings under Delaware statutory or common law: any derivative action or proceeding brought on our behalf; any action asserting a claim of breach of fiduciary duty owed by any of our directors, officers or stockholders to us or to our stockholders; any action asserting a claim against us arising pursuant to the Delaware General Corporation Law, our amended and restated certificate of incorporation or our amended and restated bylaws (as either may be amended from time to time); or any action asserting a claim against us that is governed by the internal affairs doctrine. As a result, any action brought by any of our stockholders with regard to any of these matters will need to be filed in the Court of Chancery of the State of Delaware and cannot be filed in any other jurisdiction; provided that, the exclusive forum provision will not apply to suits brought to enforce any liability or duty created by the Exchange Act or any other claim for which the federal courts have exclusive jurisdiction; and provided further that, if and only if the Court of Chancery of the State of Delaware dismisses any such action for lack of subject matter jurisdiction, such action may be brought in another state or federal court sitting in the State of Delaware. Our amended and restated certificate of incorporation and amended and restated bylaws also provide that the federal district courts of the United States of America will be the exclusive forum for the resolution of any complaint asserting a cause of action against us or any of our directors, officers, employees or agents and arising under the Securities Act. Nothing in our amended and restated certificate of incorporation and amended and restated bylaws preclude stockholders that assert claims under the Exchange Act from bringing such claims in state or federal court, subject to applicable law.
        If any action the subject matter of which is within the scope described above is filed in a court other than a court located within the State of Delaware, or a Foreign Action, in the name of any stockholder, such stockholder shall be deemed to have consented to the personal jurisdiction of the state and federal courts located within the State of Delaware in connection with any action brought in any such court to enforce the applicable provisions of our amended and restated certificate of incorporation and amended and restated bylaws and having service of process made upon such stockholder in any such action by service upon such stockholder's counsel in the Foreign Action as agent for such stockholder. Although our amended and restated certificate of incorporation and amended and restated bylaws contain the choice of forum provision described above, it is possible that a court could find that such a provision is inapplicable for a particular claim or action or that such provision is unenforceable.
     This choice of forum provision may limit a stockholder's ability to bring a claim in a judicial forum that it finds favorable for disputes with us or any of our directors, officers, other employees or stockholders, which may discourage lawsuits with respect to such claims, although our stockholders will not be deemed to have waived our compliance with federal securities laws and the rules and regulations thereunder.
Amendment of Charter Provisions
        The amendment of any of the above provisions in our amended and restated certificate of incorporation, except for the provision making it possible for our board of directors to issue undesignated preferred stock, would require approval by a stockholder vote by the holders of at least a 662/3% of the voting power of the then outstanding voting stock.
        The provisions of the Delaware General Corporation Law, our amended and restated certificate of incorporation and our amended and restated bylaws could have the effect of discouraging others from attempting hostile takeovers and, as a consequence, they may also inhibit temporary fluctuations in the market price of our common stock that often result from actual or rumored hostile takeover attempts. These provisions may also have the effect of preventing changes in our management. It is possible that these provisions could make it more difficult to accomplish transactions that stockholders may otherwise deem to be in their best interests.
Limitation of Liability and Indemnification Matters
        Our amended and restated certificate of incorporation contains provisions that limit the liability of our directors for monetary damages to the fullest extent permitted by Delaware law. Consequently, our directors will not be personally liable to us or our stockholders for monetary damages for any breach of fiduciary duties as directors, except liability for:

•any breach of the director's duty of loyalty to us or our stockholders;
•any act or omission not in good faith or that involves intentional misconduct or a knowing violation of law;
•unlawful payments of dividends or unlawful stock repurchases or redemptions as provided in Section 174 of the Delaware General Corporation Law; or
•any transaction from which the director derived an improper personal benefit.
Each of our amended and restated certificate of incorporation and amended and restated bylaws provide that we are required to indemnify our directors and officers, in each case to the fullest extent permitted by Delaware law. Our amended and restated bylaws also obligate us to advance expenses incurred by a director or officer in advance of the final disposition of any action or proceeding, and permit us to secure insurance on behalf of any officer, director, employee or other agent for any liability arising out of his or her actions in that capacity regardless of whether we would otherwise be permitted to indemnify him or her under Delaware law. We have entered and expect to continue to enter into agreements to indemnify our directors, executive officers and other employees as determined by our board of directors. With specified exceptions, these agreements provide for indemnification for related expenses including, among other things, attorneys' fees, judgments, fines and settlement amounts incurred by any of these individuals in any action or proceeding. We believe that these bylaw provisions and indemnification agreements are necessary to attract and retain qualified persons as directors and officers. We also maintain directors' and officers' liability insurance.
The limitation of liability and indemnification provisions in our amended and restated certificate of incorporation and amended and restated bylaws may discourage stockholders from bringing a lawsuit against our directors and officers for breach of their fiduciary duty. They may also reduce the likelihood of derivative litigation against our directors and officers, even though an action, if successful, might benefit us and our stockholders. Further, a stockholder's investment may be adversely affected to the extent that we pay the costs of settlement and damages.
Transfer Agent and Registrar
        The transfer agent and registrar for our common stock is Philadelphia Stock Transfer, Inc. The transfer agent and registrar's address is 2320 Haverford Rd., Ste 230 Ardmore, PA 19003.EX-4.14

 Exhibit 4.14 

Certain confidential information contained in this document, marked by [**], has been omitted because Immatics N.V. (IMTX) has determined
that the information (i) is not material and (ii) is the type that IMTX customarily and actually treats as private or confidential. 

THE UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT HOUSTON 

AND 
 IMMATICS US, INC.

  
  

AMENDMENT NUMBER 6- FACILITIES/EQUIPMENT USE AND SERVICES AGREEMENT 

This Amendment Number 6 (“Amendment”) to the Facilities/Equipment Use and Services Agreement (“Agreement”) is entered into
effective the 1st day of June 2020, by and between The University of Texas Health Science Center at Houston, (“UTHealth”) and lmmatics US, Inc. (“lmmatics”). UTHealth and
lmmatics shall be known collectively as “the Parties” and singularly as “a Party” or “the Party.” 
 WHEREAS,
the Parties previously entered into an Agreement effective September 1, 2015, as previously amended, whereby UTHealth makes available certain facilities, equipment, and personnel in support of projects; and 

WHEREAS, the Parties now desire to amend the Agreement. 

NOW, THEREFORE, the Parties agree as follows: 
  

	1.	 Section 1.1. a shall be deleted in its entirety and replaced with the following: 

“Production Suites/Administrative Space. An exclusive license to use certain production suites and administrative space located in
the Facility, described as Rooms BBS 6310, BBS 6312, BBS 6314, and a cubicle in BBS 6102 (the “Premises”). The use of Room BBS 6310 shall be for the period February 1, 2017 through December 31, 2024, BBS 6312 shall be for the
period September 1, 2015 through December 31 , 2024 and the use of Room BBS 6314 shall be for the period February 1, 2016 through December 31, 2024.” 
  

	2.	 Section 5.1 shall be deleted in its entirety and replaced with the following: 

“This Agreement shall commence as of September 1, 2015, and shall continue until December 31, 2024 (“Term”), unless
the term is otherwise limited as set forth in Section 1.1a or Section 5.2.” 
  

	3.	 Section 9 shall be deleted in its entirety and replaced with the following: 

“Compensation. In consideration for the license herein granted for the use of the Licensed Facilities and the other services
provided by UTHealth pursuant to this Agreement, lmmatics shall compensate UTHealth as follows: 
 For the period June 1, 2020 through
December 31, 2021: 
  

	 	•	 	 a comprehensive monthly fee of [**] per production suite (i.e., BBS 6310, BBS 6312, and BBS 6314) inclusive of a
[**] administrative fee and calculated in accordance with the budget set forth in Exhibit E-2 for the applicable term set forth in section 1.1a. 

 

	 	•	 	 a monthly fee of [**] for the exclusive use of a Biosafe Sepax 2 RM automated cell processing system for the same
term set forth in section 5.1. This fee is inclusive of a [**] administrative fee and covers the maintenance of the instrument. In case of breakdown, during the downtime of the instrument the samples may be processed on an identical system located
in The Judith R. Hoffberger Cellular Therapeutics Laboratory and such service will be invoiced separately. 

 Process
specific reagents and other supplies are not included in the cost set forth above and shall be procured by UTHealth and invoiced to lmmatics as a separate line item charge. Additionally, individual extra-ordinary services as set forth in
Exhibit F shall be invoiced to lmmatics as a separate line item charge. The invoices for reagents, other supplies, and extra-ordinary services shall also include a [**] administrative fee. 

 Certain confidential information contained in this document, marked by [**], has been
omitted because Immatics N.V. (IMTX) has determined that the information (i) is not material and (ii) is the type that IMTX customarily and actually treats as private or confidential. 

 

 All payments shall be made within [**] days after receipt of the invoice and mailed to the
address below or sent by electronic funds transfer: 
 The University of Texas Health Science Center at Houston 

6431 Fannin Street, MSB 5.248 

Houston, TX 77030 
 Attn: Diane
Harnden 
 For the period January 1, 2022 through December 31, 2024: 

a comprehensive monthly fee of [**] per production suite (i.e., BBS 6310, BBS 6312, and BBS 6314) inclusive of a [**] administrative fee and
calculated in accordance with the budget set forth in Exhibit E-2 for the applicable term set forth in section 1.1a. 
  

	 	•	 	 a monthly fee of [**] for the exclusive use of a Biosafe Sepax 2 RM automated cell processing system for the same
term set forth in section 5.1. This fee is inclusive of a [**] administrative fee and covers the maintenance of the instrument. In case of breakdown, during the downtime of the instrument the samples may be processed on an identical system located
in The Judith R. Hoffberger Cellular Therapeutics Laboratory and such service will be invoiced separately. 

 Process
specific reagents and other supplies are not included in the cost set forth above and shall be procured by UTHealth and invoiced to lmmatics as a separate line item charge. Additionally, individual extra-ordinary services as set forth in
Exhibit F shall be invoiced to lmmatics as a separate line item charge. The invoices for reagents, other supplies, and extra-ordinary services shall also include a [**] administrative fee. 

All payments shall be made within [**] days after receipt of the invoice and mailed to the address below or sent by electronic funds transfer:

 The University of Texas Health Science Center at Houston 

6431 Fannin Street, MSB 5.248 

Houston, TX 77030 
 Attn: Diane
Harnden” 
 4. Exhibit E2 shall be deleted in its entirety and replaced with the following: 

For the period June 1, 2020 thorugh December 31, 2021 

[**] 
 For the period January 1, 2022 thorugh
December 31, 2024 

 Certain confidential information contained in this document, marked by [**], has been
omitted because Immatics N.V. (IMTX) has determined that the information (i) is not material and (ii) is the type that IMTX customarily and actually treats as private or confidential. 

 

 [**] 

Except as provided for herein, all other terms and conditions of the Agreement effective September 1, 2015, as previously amended, shall
remain in full force and effect. 
 IN WITNESS WHEREOF, the Parties have executed this Amendment to be effective as of the first date written above. 

SIGNED: 
  

									
	IMMATICS US, INC.	  		  	THE UNIVERSITY OF TEXAS HEALTH SCIENCE AT HOUSTON
					
	By:	  	 /s/ Steffen Walter
	  		  	By:	  	 /s/ T. Kevin Dillon

	Steffen Walter	  		  	T. Kevin Dillon
	Chief Technology Officer	  	 

                          
              
	  	Sr. Executive Vice President, Chief Operating and Financial Officer
			
	Date: 6/17/2020	  		  	Date: 06/19/2020

  

			
	 APPROVED AS TO LEGAL FORM

on behalf of UTHealth
  

	By	 	 dsl 6/19/2020

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00325-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00325-of-00352.parquet"}]]